STAT+: Pharmalittle: Biotech CEOs pull in some of health care’s biggest paydays; split emerges between groups providing abortion pills
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Category: Pharmalot
STAT+: Pharmalittle: Will the Supreme Court review controversial patent rulings? GSK prepares for its consumer health spinoff
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: A Supreme Court review of a contentious patent issue would change the way pharma claims discoveries
In the coming weeks, the Supreme Court is expected to decide whether to review a…
STAT+: Pharmalittle: Teva asks U.S. Supreme Court to review skinny labeling; European Commission rebuked for Pfizer texts
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: Pharmalittle: Covid worsened antibiotic resistance; Teva and AbbVie unit settle opioid suit with San Francisco
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: ‘Eye-opening’: The pandemic accelerated antimicrobial resistance across the U.S.
Resistance to medicines for combating superbugs has considerably worsened during the pandemic, with deaths and…
STAT+: Pharmalittle: N.Y. AG claims Teva lied about its role in the opioid crisis; doctors question compounded versions of Novo weight loss drug
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Pharmalittle: Perrigo seeks FDA approval to sell birth control over the counter; 1.1 billion Covid vaccines have been wasted
Good morning, everyone, and nice to see you again after we disappeared for a needed…
STAT+: Pharmalittle: California to make its own low-cost insulin; Theranos jury finds Balwani guilty on all counts
Good morning, one and all. Damian Garde here, filling in for Ed Silverman once again…
STAT+: Pharmalittle: Merck closes in on acquisition of Seagen; Intercept declares victory after re-analyzing NASH data
Good morning, everyone. Damian Garde here, filling in for Ed Silverman as the days of…
STAT+: Pharmalittle: Some scientists want more Vertex CRISPR data; Biogen Alzheimer’s drug to get priority review
Good morning. Elizabeth Cooney here, sitting in for Ed Silverman again, wishing him sunny skies…
STAT+: Pharmalittle: Market downturn chills VC climate; drug distributors prevail in W. Va. opioids case
Good morning. Elizabeth Cooney here again, pinch-hitting for Ed Silverman. Although he sometimes makes his…
STAT+: ‘A slippery slope’: Pfizer sells a contraceptive and donated to political groups that could come after the company
Generally speaking, a company would not want to contribute to a politician whose actions could…
STAT+: ‘A slippery slope’: Drugmakers that sell contraceptives donated to political groups that could come after them
Generally speaking, a company would not want to contribute to a politician whose actions could…
STAT+: Pharmalittle: Senate Dems vet a tweaked version of drug-pricing bill; biotechs double down on developing birth control products
And so, another working week will soon draw to a close. Not a moment too…
STAT+: The near-term outlook for pharma industry earnings just got a little worse
The near-term earnings outlook for the pharmaceutical industry was revised downward by a major credit…
STAT+: Pharmalittle: Pfizer and U.S. strike $3.2 billion deal for Covid vaccine; marketing of morning-after pills shifts to mail-order options
Good morning, everyone, and nice to see you again after we took an all-too-quick, day-long…
STAT+: Pharmalittle: FDA panel urges revamped Covid boosters; White House to widen access to monkeypox vaccine
Good morning. Elizabeth Cooney here, sitting in for Ed Silverman as he takes a day…
STAT+: 100 lawmakers ask HHS to use controversial federal laws to combat high drug prices
A group of 100 federal lawmakers is urging the Biden administration to use controversial provisions…
STAT+: Pharmalittle: Retailers ration contraceptive pills as demand spikes; Supreme Court rules doctors must knowingly misprescribe opioids to be convicted
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Pharma largely failed to follow human rights principles with its Covid-19 vaccines and drugs
More than two years after the Covid-19 pandemic emerged, a new scorecard finds that 19…
STAT+: Pharmalittle: Abortion pills will be at center of legal battles; Gilead reaches $33 million settlement over patient assistance programs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: A ‘colossal financial fraud’: Gilead to get $33 million from a clinic for exploiting its HIV patient assistance program
After nearly two years of courtroom squabbling, Gilead Sciences reached a $33 million settlement with…
STAT+: Pharmalittle: Sarepta halts a Duchenne clinical trial over safety; Why the CVS Health whistleblower lawsuit comes at a pivotal moment
And so, another working week will soon draw to a close. Not a moment too…
STAT+: A CVS whistleblower lawsuit comes at a pivotal moment for the FTC’s probe of pharma and PBMs
Three years ago, a former CVS Health executive told a U.S. Senate committee hearing that…
STAT+: Pharmalittle: Senate bill would allow insulin makers to lock in profits; GSK, Novartis pledge funds for diseases that mostly affect the poor
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Industry-funded studies on cost-effectiveness often favor pricier drugs, study finds
In response to rising prices for medicines, public and private payers increasingly rely on assessments…
STAT+: Pharmalittle: U.K. inks $1.2 billion deal with Moderna for vaccine center; Top Biocon exec arrested in bribery scandal
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Senate lawmakers introduce a bill to help the FDA and the U.S. Patent Office coordinate
Amid concerns that patent reviewers disregard competitive effects on prescription drugs, a bipartisan group of…
STAT+: Pharmalittle: Medicare could have saved billions if it paid what Cuban charges; India’s drug controller accused of taking bribe
Top of the morning to you, and a fine one it is. The sun is…
STAT+: Medicare could have saved billions on drugs if it paid what Mark Cuban charges at his new pharmacy
Amid growing anger over the cost of medicines, a new analysis finds that Medicare could…
STAT+: European Commission investigates Vifor for ‘disparaging’ its only rival in iron deficiency market
The European Commission has opened an investigation into allegations that Vifor Pharma spread misleading information…
STAT+: Pharmalittle: Merck is eyeing Seagen to beef up its cancer drug portfolio; Lawmakers want GAO to probe PBMs
Good morning, everyone, and welcome to another working week, although today is actually a holiday…
STAT+: Pharmalittle: FTC warns pharma and PBMs about rebate schemes; WTO reaches Covid vaccine patent waiver deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: WTO reaches a deal on Covid vaccine patent waivers, but industry and advocates remain unhappy
After nearly two years of talks, the World Trade Organization reached an agreement to temporarily…
STAT+: FTC puts drugmakers and PBMs on notice that it will crack down on illegal rebate schemes
In a notable move, the Federal Trade Commission put drugmakers and pharmacy benefit managers on…
STAT+: Pharmalittle: CVS whistleblower suit details plans to boost consumer drug costs; Roche reports negative Alzheimer’s trial results
Hello, everyone, and how are you today? Another dank cloudy cover greeted us this morning,…
.jpg)
STAT+: A ‘veritable playground’: CVS whistleblower details how patients were charged higher drug prices
The conversation reflected frustration and disbelief. A woman had called SilverScript, which runs one of…
STAT+: Pharmalittle: FDA panel to review Covid shots for young children; Shionogi to license antibiotic to dozens of poor countries
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: FDA oversight of pharma manufacturing facilities plunges during the pandemic
Each year, the Food and Drug Administration tracks its progress inspecting pharmaceutical manufacturing facilities and…
STAT+: In a first-of-its-kind deal, major drugmaker licenses antibiotic production for low-income countries
In a first-of-its-kind arrangement, Shionogi has reached an agreement with the Global Antibiotic Research and…
STAT+: Pharmalittle: Lawmakers urge FTC to probe blood thinner prices; EU pressures Covid vaccine makers to renegotiate contracts
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: A widely anticipated ALS drug wouldn’t be cost effective if priced the same as an older rival
Amid growing demand for ALS treatments, a preliminary analysis finds an experimental medicine that may…
STAT+: FDA approved more cancer drugs than EMA, but they may not have always benefited patients
Amid rising pressure to endorse new medicines, U.S. regulators greatly outpaced their European counterpart in…
STAT+: Pharmalittle: Canada OKs ALS drug still waiting FDA approval; WTO talks on Covid patent waiver are down to the wire
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Simmering disputes persist as Covid patent waiver talks come down to the wire
On Sunday, the World Trade Organization will hold a long-delayed ministerial conference to craft a…
STAT+: Pharmalittle: FDA panel endorses Bluebird Bio gene therapy for rare disease; GSK touts RSV vaccine trial results
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: FDA decision on Novavax Covid shot could be delayed; new drug prices rose 20% annually in recent years
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: How high? Prices for newly launched medicines rose 20% annually, analysis finds
Talk about inflation Amid ongoing angst over prescription drug costs, a new analysis finds that…
STAT+: Pharmalittle: FDA panel endorses Novavax Covid shot; FTC to probe pharmacy benefit managers
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…